SWOG Cancer Research Network
15K posts
@SWOG
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956.
Important perspective led by @DDoroshow and the Lung-MAP team in @JCO_ASCO on defining primary vs acquired resistance to immune checkpoint inhibitors in NSCLC clinical trials. Critical as we develop the next generation of post-ICI studies.
After #ASCO26, @ChristianRolfo, @OSUCCC_James, sat down with @WaqasHaqueMD to discuss the evolving role of #MET amplification in stage IV recurrent non-small cell #LungCancer (#NSCLC) and a phase 2 study of subcutaneous #amivantamab. Watch here! oncdata.com/new-door-in-lu…
The @UHCancerCenter is highly active in clinical trials through NCORP and NCTN. Dr. Jeffrey Berenberg, our highly respected senior investigator, serves as our senior principal investigator and has been a key leader in advancing this important work. NCORP/NCTN studies are equally important to industry-sponsored trials. They help bring high-quality cancer clinical trials to communities and ensure that research addresses the real needs of patients, including those in underserved and geographically isolated areas. A recent podcast by The Cancer Letter featuring NCORP leaders highlights how cancer clinical trials are becoming increasingly complex. While regulatory oversight is essential for patient safety and research quality, growing administrative requirements can slow progress and take valuable time away from patient care and research execution. The discussion also emphasizes major challenges facing clinical trials today: workforce shortages, staff turnover, limited funding, low patient participation, and the difficulty of bringing trials to underserved communities. These issues directly affect access, trust, and the ability to deliver high-quality cancer care. The key message is clear: community involvement is essential. Clinical trials must reach patients where they live. Better outreach, education, training, and thoughtful use of tools such as AI can help reduce barriers and make cancer research more efficient, accessible, and patient-centered. Cancer research works best when the community is not only included, but truly engaged. This is a great podcast to listen to. youtube.com/watch?v=ummAFQ…
Very excited to present our trial in progress at #ASCO26 S1900J is enrolling patients in NSCLC with MET amplification as primary driver to be treated with Amivantamab sc @SWOGonc @LungMAP @JhanelleGray @drgandara @ReckampK @OSUCCC_James @OhioStateMedOnc @metcrusaders @ASCO
First interim analysis of SWOG S1823/GCC.1: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients with early-stage #TesticularCancer. Presentation by @LuciaNappi4 @VanProstateCtr. #ASCO26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4dOKJNq @ASCO @SWOG
